Navigation Links
Shopko Launches Mobile Pharmacy App to Maximize Customer Convenience
Date:1/10/2012

ge buyouts, equity, debt, and other investments in market-leading companies that can benefit from its in-house operating professionals and experience. Headquartered in Green Bay, Wisconsin, the $2 billion retailer operates 149 stores in 13 states throughout the Midwest, Mountain and Pacific Northwest regions. Retail formats include 134 Shopko stores, providing quality name-brand merchandise, great values, pharmacy and optical services in small to mid-sized cities; 5 Shopko Express Rx stores, a convenient neighborhood drugstore concept; and 10 Shopko Hometown locations, a smaller concept store developed to meet the needs of rural communities. For more information, visit www.shopko.com.


'/>"/>
SOURCE Shopko
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System
2. Revation Systems Launches an Accessible Virtual Care Solution for Healthcare Organizations
3. Verenium Launches Second Enzyme Product for Oilfield Services
4. Successful Diabetes Product Launches Balance Digital & Traditional Public Relations Tools
5. Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity
6. theVisualMD Launches a Revolutionary New Visual Path to Wellness
7. Mylan Launches First Generic Version of Teveten® Tablets
8. Doximity Launches ExpertFinder to Match Clinical Need with Clinical Experts
9. CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line
10. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Securities Laws Violations by Invacare Corporation
11. Mylan Launches Generic Version of Toprol-XL® Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Hurel Corporation ("Hurel"), a world-leading provider ... platforms, today announced the appointment of James ... Board of Directors. Dr. MacDonald is the former Executive ... Institute ("SPRI"), which was the pharmaceutical development arm of ... Co. in 2009. Over a career that ...
(Date:5/21/2013)... ALLENTOWN, Pa. , May 21, 2013  Lehigh ... additional TRU-D SmartUVC TM devices, adding to its ... With seven devices taking up residence within the network, ... in the U.S. to proactively combat superbugs and provide ... Short for Total Room Ultraviolet Disinfector, TRU-D – the ...
(Date:5/21/2013)... May 21, 2013  Janssen R&D Ireland (Janssen) ... the global Phase 3 PROMISE study demonstrating that ... led to sustained virologic response 12 weeks after ... of treatment-experienced genotype 1 chronic hepatitis C adult ... of liver fibrosis, when administered once daily with ...
Breaking Medicine Technology:Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... Disease Week data highlight effects of AMITIZA in ... ... results indicated that,treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant ... were presented at Digestive Disease Week (DDW) 2008, the,largest annual international ...
... Five Oral Presentations at ASCO Annual Meeting Will Further ... Front-line Multiple Myeloma -, CAMBRIDGE, Mass., May 16 ... new data from VELCADE,clinical studies are scheduled to be ... Annual Meeting in Chicago, Illinois, May 30 -,June 3, ...
Cached Medicine Technology:New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 2New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 3New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 4New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 5New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 6New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C) 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
(Date:5/21/2013)... from SOURCE XT one of the largest, post-approval ... today at EuroPCR 2013 show good clinical outcomes in ... for all access approaches, valve sizes and delivery systems. ... consecutively enrolled patients (mean age 81.5 years) undergoing TAVI ... in 17 countries between July 2010 and October 2011. ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 According to a ... Rethink the Use of Botox,” Botox injections have ... their approval in 2002 (Go to goo.gl/8iYbD). Although it is ... popular with men. The injection makes facial wrinkles less visible ... injection last for about three months. This means that people ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Phoseon Technology ... at the 20th Annual IMI European Ink Jet ... proven market leader, Phoseon continues to invest in product ... the adoption of UV LED curing in printing applications. ... families on the market offering both air cooled and ...
(Date:5/21/2013)... 2013 MedMar Healing Center announces ... Second Harvest Food Bank. Twenty-eight businesses, including MedMar Healing Center, ... food drive. The goal is to raise food to help ... facing their families in recent years. , “We like ... those in need,” explains Douglas Chloupek of MedMar Healing Center. ...
(Date:5/21/2013)... two proteins, thrombospondin-1 and prosaposin, play in discouraging ... a five-amino acid fragment of prosaposin that significantly ... breast and lung cancer. The findings suggest that ... a variety of cancers. , The study ... Children,s Hospital, Vivek Mittal, PhD, at Weill Cornell ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3
... Way to Fight Rare, but Deadly, Side Effect ... St. Luke,s Medical Center have developed a technique ... from natalizumab (Tysabri(R)), a drug that fights multiple ... called progressive multifocal leukoencephalopathy (PML)."This virus looks like ...
... J. Betters, president and chief executive officer of C. ... submitted an offer to purchase the former Aliquippa Hospital. ... awaiting a response from the hospital property owners and ... future uses for the hospital property., ...
... a woman blind in one eye. As she copes with ... uninjured eye begins to blur, and the eye becomes red ... ophthalmia, occurs when vision is lost in one eye through ... attacks the remaining healthy eye. Left untreated, a person can ...
... These patients were twice as likely to get clot-busting drug, ... who get to a hospital no more than an hour ... as likely to get the powerful clot-dissolving drug that is ... Of the more than 100,000 people treated for stroke at ...
... United BioSource Corporation (UBC) and CogState ... renew the strategic relationship the two companies ... CogState,s ClinicalTrials software for computerized cognitive testing ... and UBC remain committed to supporting cognitive ...
... Feb. 18 Spurred by seizures of vital doctor-prescribed ... Zealand to U.S. citizens, the publishers of three Seniors, ... Food and Drug Administration to halt the arbitrary seizures ... medicines to U.S. seniors and others.The publishers are Frank ...
Cached Medicine News:Health News:Research Brings New Hope to Multiple Sclerosis Patients 2Health News:New surgical implant tested at U-Iowa prevents total blindness 2Health News:Fast Arrival at Hospital After Stroke Pays Off 2Health News:Fast Arrival at Hospital After Stroke Pays Off 3Health News:Seniors' Website Publishers Ask President to Curtail FDA Seizures of Vital Medicines 2
... system was expressly designed to obtain the ... special source and an equally special power ... particular high energy impulses with constant peak ... 'top-flat shaped') allow storage of enough energy ...
... Derm is a KTP laser, very compact ... nm (frequency doubled Nd:YAG) for dermatologic treatments. ... comfortable color LCD Touch-screen. Maximum power ... 0.3, 0.5, 0.7 and 1.0 mm. SmartLite ...
... Erbium (Er:YAG) laser is the ideal instrument ... Smart 2940 Plus, the majority of surface ... a wide range of scar tissue, with ... most cases with the elimination of anaesthetics, ...
... is the result of DEKA s ... of three different methods capable of ... skin. This treatment is designed to ... through the combined action of a ...
Medicine Products: